TTI-101
Idiopathic Pulmonary Fibrosis (IPF)
Key Facts
About Tvardi Therapeutics
Tvardi Therapeutics is a Houston-based biotech focused on developing oral STAT3 inhibitors to treat fibrosis-driven, inflammatory, and proliferative diseases. Founded in 2017, the company has progressed its lead asset, TTI-101, into Phase 2 trials for IPF and liver cancer. Its strategy leverages a novel, direct STAT3 inhibition platform with broad therapeutic potential, recently bolstered by a 2025 merger with Cara Therapeutics to enhance resources and pipeline depth.
View full company profileAbout Tvardi Therapeutics
Tvardi Therapeutics is a Houston-based biotech focused on developing oral STAT3 inhibitors to treat fibrosis-driven, inflammatory, and proliferative diseases. Founded in 2017, the company has progressed its lead asset, TTI-101, into Phase 2 trials for IPF and liver cancer. Its strategy leverages a novel, direct STAT3 inhibition platform with broad therapeutic potential, recently bolstered by a 2025 merger with Cara Therapeutics to enhance resources and pipeline depth.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| CAL101 | Calluna Pharma | Phase 2 |
| NVP-13 | Velvio | Pre-clinical |